HIF, Hypoxia Research & Stem Cell News

International Stem Cell Corporation, Through Its Subsidiary Lifeline Cell Technology, Announces the Launch and Sale of New Products into the Human Cell Research Market

International Stem Cell Corporation, announces that it has launched fifteen new human cell culture products into the commercial research markets over the last twelve months through its wholly-owned subsidiary, Lifeline Cell Technology, (Walkersville, MD), leading to a 12-month average month-to-month revenue growth of 50%. ISCO, the parent company, is the first company to create human “parthenogenetic” stem cells from unfertilized eggs. Parthenogenetic stem cells not only solve ethical problems, but also promise to minimize immune-rejection by providing cells that can be immune-matched to large segments of the population.

These products represent milestone achievements in ISCO’s strategy of generating revenue from the sale of research products, while building infrastructure from that effort to expand the manufacturing and quality control capacities ISCO needs to commercialize the therapeutic applications of human parthenogenetic stem cells.

One of its newest and most promising products consist of “xeno-free” human cells and culture reagents that allow researchers to study embryonic stem cells without contamination from animal (non-human) components. These products meet the needs for stem cell research to be done using “human-only” systems. Other products include Lifeline’s living human cells and reagents for research and drug development into cardiovascular, kidney, lung, nerve, eye and skin disease. Lifeline is continuing to develop unique reagents and media for the growing field of stem cell research. The “Lifeline” brand of products consist of human cells and the culture reagents and growth factors needed to grow the cells.

According to Jeffrey Janus, CEO of Lifeline, “We are proud of the quality of our new products, as reflected in the sales growth they are exhibiting in the human cell research markets. We look forward to launching more new products into the growing markets for stem cell research and drug development. These products will contribute to the success of ISCO, not only by supporting ISCO’s therapeutic research, but also through the development of critical manufacturing and quality control systems necessary for ISCO to produce therapeutic human cells in the future.”

Lifeline’s products can be found at www.lifelinecelltech.com
For more news and information on International Stem Cell Corporation please visit www.IRGnews.com/coi/ISCO where you can find the CEO’s video, a fact sheet on the company, investor presentations, and more.

from http://www.internationalstemcell.com

Related posts:

• BioTime Opens Asian Subsidiary to Sell Stem Cell Tools, Therapies
  Stem-cell firm BioTime said this week that it will open a subsidiary in China called BioTime Asia to expand its stem cell therapeutics and research tools to the Asian market.

  BioTime

• The Jordanian Stem Cell Company Acquires Stem Cell Technology From Stemedica International S.A. First Clinical Trail Anticipated To Begin Early 2010
  Stemedica Cell Technologies, Inc., (“Stemedica”), a world leader in stem cell research and manufacturing, announced the signing of an agreement today for its breakthrough stem cell and related technology.
• Virgin Launches Stem Cell Bank in Qatar

  Click here to view the embedded video.

  The British mega-brand Virgin has launched a stem-cell bank in Qatar. The country has lofty goals of becoming the world leader in stem cell technologies, and unlike in the West,

• Stem Cell Therapeutics Corp. Announces the FDA Has Lifted Its Clinical Hold on the Phase IIb Stroke Trial

  Click here to view the embedded video.

  Stem Cell Therapeutics Corp. is pleased to announce the U.S. Food and Drug Administration (FDA) has provided a verbal confirmation to remove its clinical hold placed on NTx®-265 on September

• Russia stem cell firm sees post-IPO market cap at 28.000.000 USD
  Russia’s Stem Cell Institute said on Wednesday it plans to raise up to 165 million roubles ($5.53 million) in what will be the country’s first initial public offering since the

If you need more information about STEM CELLS please visit Latest Stem Cells News

This post comes from Latest Stem Cells News
(Digital Fingerprint: 0f6d53ed7d5f01118cf01c21fc9b9d58)